Cantor Fitzgerald Reaffirms Overweight Rating for ALX Oncology (NASDAQ:ALXO)

Cantor Fitzgerald restated their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a report published on Tuesday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2024 earnings at ($2.69) EPS.

Several other research analysts have also weighed in on ALXO. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research report on Tuesday, August 13th. UBS Group lowered their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a report on Friday, August 16th. Lifesci Capital downgraded ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, Stifel Nicolaus restated a “hold” rating and set a $3.00 target price (down from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.50.

ALX Oncology Trading Down 3.0 %

Shares of ALXO opened at $1.29 on Tuesday. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $68.04 million, a P/E ratio of -0.43 and a beta of 1.03. The stock’s fifty day simple moving average is $1.69 and its 200 day simple moving average is $5.57. ALX Oncology has a twelve month low of $1.25 and a twelve month high of $17.83.

Hedge Funds Weigh In On ALX Oncology

Several large investors have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co bought a new position in shares of ALX Oncology during the first quarter worth about $27,000. EntryPoint Capital LLC bought a new position in ALX Oncology in the first quarter worth about $32,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after acquiring an additional 5,200 shares during the last quarter. Rhumbline Advisers lifted its holdings in ALX Oncology by 10.8% in the second quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after acquiring an additional 5,360 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after buying an additional 6,080 shares during the last quarter. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.